A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study.
Fiche publication
Date publication
juillet 2017
Journal
Alcohol and alcoholism (Oxford, Oxfordshire)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TROJAK Benoît
Tous les auteurs :
Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, Trojak B, Paille F, Detilleux M
Lien Pubmed
Résumé
Alcohol dependence is a major public health issue with a need for new pharmacological treatments. The ALPADIR study assessed the efficacy and safety of baclofen at the target dose of 180 mg/day for the maintenance of abstinence and the reduction in alcohol consumption in alcohol-dependent patients.
Mots clés
Adult, Alcohol Drinking, drug therapy, Alcoholism, drug therapy, Baclofen, administration & dosage, Craving, drug effects, Double-Blind Method, Female, GABA-B Receptor Agonists, adverse effects, Humans, Male, Middle Aged
Référence
Alcohol Alcohol.. 2017 Jul 1;52(4):439-446